PDRN Cytotoxicity Testing: Complete In Vitro Biocompatibility Evaluation Guide

PDRN cytotoxicity testing is a fundamental in vitro biocompatibility study that determines whether polydeoxyribonucleotide-based products exert harmful effects on mammalian cells. Conducted in accordance with ISO 10993-5, this assay provides essential safety evidence for the regulatory registration of PDRN injectables, wound-care devices, and cosmetic formulations. This guide covers the testing principles, sample categories, methodologies, acceptance criteria, and practical applications of PDRN cytotoxicity evaluation.

Technical Overview

PDRN (polydeoxyribonucleotide) is a mixture of linear deoxyribonucleotide polymers, typically with chain lengths between 50 and 2,000 base pairs and molecular weights ranging from approximately 50 to 1,500 kDa. It is most commonly derived from salmon milt DNA through controlled extraction and depolymerization, followed by purification to pharmaceutical or cosmetic grade. PDRN is known to activate the adenosine A2A receptor, promote fibroblast proliferation, stimulate collagen synthesis, and accelerate tissue repair, which explains its widespread use in injectable skin boosters, regenerative aesthetic treatments, and wound healing products.

Because PDRN-containing products frequently contact human tissue either through injection or damaged skin, cytotoxicity testing is a mandatory first step in the biological safety evaluation cascade. The test determines whether the material itself, or substances leaching from it, can cause cell death, inhibit cell growth, or alter cellular metabolism. The internationally recognized framework for this evaluation is ISO 10993-5 (Tests for in vitro cytotoxicity), supported by ISO 10993-12 (Sample preparation and reference materials).

The core principle of the assay involves exposing a standardized mammalian cell culture to the PDRN test sample or its extract, then quantifying cell viability through a colorimetric or fluorescent endpoint. Results are compared against negative and positive controls, and cell viability of 70% or greater relative to the blank control indicates the sample is considered non-cytotoxic.

Testing Samples

PDRN Raw Materials and API-Grade Powders

Bulk PDRN sodium salt powders are dissolved in cell culture medium or phosphate-buffered saline to generate stock solutions at physiologically relevant concentrations. Testing of raw materials verifies that the extraction, depolymerization, and purification processes have not introduced residual solvents, heavy metals, or degradation byproducts with cytotoxic potential.

Injectable PDRN Solutions

Sterile PDRN solutions for injection, commonly supplied at concentrations such as 1.5% (15 mg/mL) in pre-filled syringes, are tested as delivered and in serial dilution series. This approach captures any cytotoxic contribution from the formulation itself, the primary packaging, or sterilization residues.

Topical and Cosmetic Formulations

Creams, serums, gels, essences, and sheet masks containing PDRN are prepared by two-phase extraction using both polar (culture medium, water) and non-polar media, ensuring that leachable substances of different polarities are evaluated.

PDRN-Combined Biomaterials and Devices

Hydrogels, collagen or hyaluronic acid scaffolds, wound dressings, microneedle patches, and drug-eluting matrices that incorporate PDRN are extracted according to the surface-area or mass-based ratios defined in ISO 10993-12, typically 0.1 g/mL for irregular porous solids or 6 cm²/mL for sheet materials.

Testing Items

A comprehensive PDRN cytotoxicity evaluation typically includes the following endpoints:

• Quantitative cell viability measurement using MTT, CCK-8, WST-1, or resazurin assays
• Cell proliferation analysis following exposure periods of 24, 48, and 72 hours
• Morphological observation of cells under phase-contrast microscopy with reactivity grading
• Membrane integrity assessment through LDH release or neutral red uptake testing
• Metabolic activity evaluation via mitochondrial dehydrogenase function
• Dose-response relationship determination across a concentration gradient
• Cytotoxicity grading on the ISO 10993-5 scale from Grade 0 to Grade 4

Testing Methods

Sample Preparation and Extraction

Test articles are prepared under aseptic conditions. Solid or semi-solid materials are extracted in complete culture medium at 37°C for 24 ± 2 hours using standardized ratios from ISO 10993-12. Liquid PDRN products may be tested directly at 100% concentration or diluted in medium to create a dilution series such as 100%, 50%, 25%, 12.5%, and 6.25%. Extraction pH and osmolality are recorded, since extreme shifts can produce apparent cytotoxicity unrelated to the PDRN molecule itself.

Indirect Contact (Extract) Method

L929 mouse fibroblasts, the preferred cell line under ISO 10993-5, are seeded in 96-well plates at approximately 1 × 10⁴ cells per well and cultured to a confluent monolayer. Extracts are applied to the monolayer and incubated at 37°C in a humidified atmosphere with 5% CO₂. BALB/c 3T3 cells, V79 cells, or human dermal fibroblasts may be used as alternatives depending on the intended clinical application.

Direct Contact Method

For materials where extract testing may not capture the full interaction, the test sample is placed directly onto the cell monolayer with a sterile overlay to ensure contact. This method is sensitive to physical irritation and leaching behavior at the material-cell interface and is frequently applied to PDRN-loaded dressings and films.

MTT Assay Procedure

Following the exposure period, MTT solution (5 mg/mL) is added to each well and incubated for approximately 4 hours. Viable cells with active mitochondrial dehydrogenases convert the yellow tetrazolium salt into purple formazan crystals, which are solubilized in DMSO or isopropanol. Absorbance is measured at 570 nm with a reference wavelength of 630 nm. Cell viability is calculated as: Viability (%) = 100 × (OD sample − OD blank) / (OD negative control − OD blank).

Controls and Acceptance Criteria

Each experiment includes a negative control (high-density polyethylene or plain culture medium) and a positive control (such as 0.64% phenol solution or sodium dodecyl sulfate), both of which must respond as expected for the assay to be valid. All conditions are tested in triplicate at minimum. According to ISO 10993-5, a test sample is considered non-cytotoxic when mean cell viability remains at or above 70% of the blank control. Qualitative grading is assigned as follows:

• Grade 0: No reactivity, discrete intact cells, viability near 100%
• Grade 1: Slight reactivity, less than 20% of cells affected
• Grade 2: Mild reactivity, 20% to 49% of cells affected
• Grade 3: Moderate reactivity, 50% to 70% of cells affected
• Grade 4: Severe reactivity, near-complete cell destruction, viability below 30%

A grade of 2 or lower is generally acceptable for most product categories, while grades 3 and 4 trigger formulation investigation or additional testing.

Applications

PDRN cytotoxicity testing supports a broad range of development and regulatory objectives:

• Biological safety documentation for medical device registration submissions under NMPA, FDA, and EU MDR frameworks
• Safety verification of injectable PDRN products used in mesotherapy, skin booster, and regenerative aesthetic procedures
• Preclinical evaluation of PDRN wound healing dressings and tissue engineering scaffolds
• Safety dossier support for PDRN-containing cosmetic products placed on regulated markets
• Batch release testing and stability program support for sterile PDRN formulations
• Formulation optimization and excipient or packaging compatibility screening during research and development
• Complementary data generation alongside sensitization, irritation, and genotoxicity studies in a full ISO 10993 evaluation plan

FAQ

What standard governs PDRN cytotoxicity testing?

ISO 10993-5 is the primary standard for in vitro cytotoxicity evaluation, with sample preparation performed according to ISO 10993-12. These standards are accepted by major regulatory authorities worldwide, including NMPA, FDA, and European notified bodies.

Which cell line is most commonly used?

The L929 mouse fibroblast line is the preferred and most widely accepted cell line for ISO 10993-5 testing. Human dermal fibroblasts are increasingly used for PDRN products intended for dermal injection, as they better reflect the actual target tissue.

What is the acceptance criterion for a passing result?

A mean cell viability of 70% or greater relative to the negative control indicates the sample is non-cytotoxic. Combined with qualitative microscopy, a reactivity grade of 2 or lower is typically required for regulatory acceptance.

Can PDRN products show false cytotoxicity?

Yes. Abnormal pH, elevated osmolality, or high sodium ion concentration from PDRN sodium salt solutions can reduce viability without true toxic action. Dilution series testing and physicochemical measurement of the extract help distinguish formulation artifacts from genuine cytotoxicity.

How long does the testing process take?

A standard in vitro cytotoxicity study, including cell culture, extraction, exposure, endpoint measurement, and report issuance, is typically completed within 2 to 4 weeks, depending on sample complexity and whether repeat or confirmatory testing is required.

Is cytotoxicity testing sufficient for full biocompatibility approval?

No. Cytotoxicity is the foundational test in the ISO 10993-1 evaluation framework. Depending on body contact type and duration, additional studies such as sensitization, intracutaneous irritation, acute systemic toxicity, genotoxicity, and hemocompatibility may be required to complete the biological safety file.